Benevolentai Bio Ltd. has discovered imidazopyridazine derivatives acting as high-affinity nerve growth factor receptor (NTRK1) and/or BDNF/NT-3 growth factor receptor (NTRK2) and/or NT-3 growth factor receptor (NTRK3) inhibitors reported to be useful for the treatment of atopic dermatitis.
Forendo Pharma Oy has presented aldo-keto reductase family 1 member C3 (AKR1C3) and/or prostaglandin F2-α synthase inhibitors reported to be useful for the treatment of acne, cancer, alopecia, obesity, chronic obstructive pulmonary disease, dysmenorrhea, endometriosis and polycystic ovary syndrome, among others.
Shanghai Xucheng Pharmatech Co. Ltd. has divulged retinoid acid receptor γ (RARγ) agonists reported to be useful for the treatment of acne, psoriasis, ichthyosis, keratosis, skin hyperpigmentation and dry eye.
Zhejiang Hisun Pharmaceutical Co. Ltd. and Shanghai Aryl Pharmtech Co. Ltd. have disclosed mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1) inhibitors reported to be useful for the treatment of systemic lupus erythematosus, psoriasis, inflammation and cancer.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has described nonreceptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of psoriasis, asthma, type 1 diabetes, inflammatory bowel disease, gout, multiple sclerosis, rheumatoid arthritis and TNF receptor-associated periodic syndrome (TRAPS), among others.
Hand-foot syndrome (HFS), or palmoplantar erythrodysesthesia, is a dermatological toxicity produced by the fluoropyrimidine chemotherapy agents capecitabine and fluorouracil and affects 43-71% of patients.
Amplifica Holdings Group Inc. has closed a US$11.8 million series A preferred stock financing, the funds from which will be used to advance the development of its proprietary compounds for the treatment of androgenic alopecia in males and females.